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Sphingosine-1-phosphate (S1P), which acts as both the extracellular and intracellular 
messenger, exerts pleiotropic biological activities including regulation of embryonic 
development, formation of the vasculature, vascular barrier integrity, vascular tonus and 
lymphocyte trafficking. Many of these S1P actions are mediated by five members of the 
G protein-coupled S1P receptors (S1P1~S1P5) with overlapping but distinct coupling to 
heterotrimeric G proteins. S1P1 couples exclusively to Gi whereas S1P2 and S1P3 couple 
to multiple G proteins. S1P2 and S1P3 prefer G12/13 and Gq, respectively, among others. 
The biological activities of S1P are based largely on the cellular actions of S1P on 
migration, adhesion and proliferation. Notably, S1P often exhibits bimodal effects in 
these cellular actions in a receptor subtype-specific manner. For example, S1P1 mediates 
cell migration toward S1P, i.e. chemotaxis, via Gi/Rac pathway whereas S1P2 mediates 
inhibition of migration toward a chemoattractant, i.e. chemorepulsion, via G12/13/Rho 
pathway which induces Rac inhibition. In addition, S1P1 mediates stimulation of cell 
proliferation through the Gi-mediated signaling pathways including phosphatidylinositol 
3-kinase (PI3K)/Akt and ERK whereas S1P2 mediates inhibition of cell proliferation 
through mechanisms involving G12/13/Rho/Rho kinase/PTEN-dependent Akt inhibition. 
These differential effects of S1P receptor subtypes on migration and proliferation lead to 
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bimodal regulation of various biological responses. An observed biological response is 
likely determined by an integrated outcome of the counteracting signals input by S1P 
receptor subtypes expressed in the cells. More recent studies identified the new 
intracellular targets of S1P; S1P acts as the intracellular messenger to bind to the 
inflammatory signaling molecule TRAF2 downstream of TNF receptor and to histone 
deacetylases HDAC1 and HDAC2, resulting in activation of NF-B and inhibition of 
histone deacteylation, respectively. Development of S1P receptor agonists and 
antagonists with improved receptor subtype-selectivity and their optimal drug delivery 
system augments useful actions and attenuates deleterious effects of S1P, thus providing 
novel therapeutic tactics. Inhibitors or modulators of S1P-synthesizing and 
-metabolizing enzymes also could be potential therapeutic tools.   
 




Introduction        
Sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), 
lysophosphatidylserine and lysophosphatidylinositol constitute lysophospholipid 
mediators and are attracting increasing interest in cell signaling for the past decade. 
Among these lysophospholipid mediators, S1P and LPA are much better characterized 
than the others. It is now recognized that the S1P signaling system comprises S1P 
synthesizing/degrading enzymes [1,2], membrane S1P transporters [3,4], S1P carrier 
proteins in the plasma [5], and five members of the G protein-coupled S1P-specific 
receptor subtypes, S1P1~S1P5 [6-8]. S1P plays crucial roles in embryonic development 
and post-natal homeostasis in the cardiovascular, immune and nervous systems [9-13]. 
The S1P signaling system is also implicated as the target of therapeutic intervention in a 
variety of human diseases; multiple sclerosis, a debilitating autoimmune disease, is now 
treated with the S1P receptor agonist prodrug FTY720 [14], whose phosphorylation 
product downregulates S1P1 in lymphocytes to inhibit their recirculation, thus resulting 
in lymphopenia and attenuated immune reaction [12]. In addition, animal studies 
suggest that targeting the S1P signaling system is a promising strategy for inhibiting 
vascular hyperpermeability and modulating angiogenesis [13, 15, 16]. Here, we will 
overview the signaling mechanisms underlying S1P regulation of biological functions 
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and the roles of S1P in diseases. 
 
S1P synthesis and metabolism  
S1P is generated within cells through phosphorylation of sphingosine by 
sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) (Figure 1) [1], which 
share a conserved catalytic domain, but are distinct in other aspects including their 
structures of non-catalytic domains and expression patterns. S1P is either 
dephosphorylated by S1P phosphatases (SPP1 & SPP2) [17] and lipid phosphate 
phosphatases (LPP1~LPP3 ) [18] to convert into sphingosine, or degraded by S1P lyase 
(SPL) to ethanolamine phosphate and hexadecenal [2], the latter reaction serving as the 
exit from sphingolipid metabolic pathway (Fig. 1). SPPs and SPL, both of which are 
highly specific for S1P, reside predominantly in the endoplasmic reticulum, while LPPs 
dephosphorylate a range of substrates including S1P.  
SphK1-knockout (KO) mice are phenotypically normal except for a 60 % reduction 
in plasma and serum S1P concentrations compared to wild-type mice [19]. However, 
tissue S1P levels in SphK1-KO mice are similar to wild-type mice. SphK2-KO mice are 
also phenotypically normal and exhibit a 25% reduction in plasma S1P concentrations 
[20]. Thus, SphK1 plays a major role in maintaining plasma and serum S1P tone, and 
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SphK2 compensates for SphK1 in maintaining tissue S1P in the absence of SphK1. 
SPL-KO mice display markedly high levels of S1P in tissues and serum with 
accumulation of ceramide and long chain bases, resulting in multi-organ damages with 
pro-inflammatory responses and altered lymphocyte and neutrophil distribution [21, 22]. 
LPP3 maintains S1P level at a low level in the thymus, thus playing a key role in T 
lymphocyte exit to the blood from the thymus [23]. 
SphKs and S1P-metabolizing enzymes play important roles not only in the 
production and degradation of S1P but also in controlling cellular levels of 
sphingolipids including sphingosine and its metabolic precursor ceramide. In contrast to 
S1P, these sphingolipid species exert growth inhibitory and proapoptotic effects when 
their cellular levels rise, through multiple mechanisms including activation of protein 
phosphatases and inhibition of Akt [1, 2, 24]. Since S1P exhibits anti-apoptotic or 
survival effects on a variety of cell types, the balance of S1P and ceramide levels is 
implicated in the determination of cell fate, i.e. survival or death under certain 
conditions. 
 
Blood S1P and S1P transporters  
In the mammalian body, there is a steep S1P concentration gradient across the 
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capillary wall [25]: the plasma S1P concentration is around 500 nM, which is 
considered to be markedly higher than that in the tissue interstitial fluid. The majority of 
plasma S1P derives from red blood cells [26], which express SphK1 but lack S1P 
degrading enzymes and thus serve as a supplier of S1P in blood, while the remaining of 
plasma S1P is released from other cells, particularly endothelial cells [27]. Indeed, 
anemia causes a reduction in the plasma S1P level. Release of S1P from erythrocytes 
strictly requires acceptor plasma proteins, mostly HDL and albumin [5]. The major part 
of plasma S1P is bound to HDL (~60%), albumin (~30%) and other plasma proteins, 
with only a few percentages of total S1P circulating in a free form. Plasma S1P is 
crucial in maintaining vascular integrity, which is achieved by endothelial 
S1P1-mediated stabilization of adherence junctions [16, 28]. At least a part of beneficial 
effects of HDL, including activation of eNOS, atheroprotection and myocardial 
protection from ischemia/reperfusion injury, are suggested to be mediated by 
HDL-bound S1P [29].  
S1P is released out of erythrocytes via a transmembrane S1P transporter. Although 
ABC family transporters have been implicated in S1P export from erythrocytes, the 
exact molecular entity of an S1P transporter remains inconclusive [3]. In a zebrafish 
mutant miles apart, loss of function mutation of S1P2 results in an anomaly termed 
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cardia bifida (two primordial heart tissues remaining separated) [30]. In a different 
zebrafish mutant ko157, which also shows cardia bifida, the major facilitator 
superfamily type transporter, Spns2, was mutated and cardiac defects in ko157 mutant 
was rescued by S1P injection [4]. Zebrafish Spns2 and its mammalian counterpart were 
found to function as a transporter for S1P and FTY720 phosphate.  
 
Expression of S1P receptors  
S1P1, S1P2 and S1P3 are broadly expressed in most of organs and mediate diverse 
actions of S1P (Table 1) [6-8, 11]. Detailed expression patterns of S1P receptors in 
tissues were defined by analyzing mice in which -galactosidase (LacZ) reporter gene 
was knocked into the receptor gene loci. S1P1, which was originally cloned from 
vascular endothelial cells, is detected in the endothelium in the lung, heart and liver of 
S1P1+/LacZ mice [9]. In the lung, S1P1 is also expressed in vascular smooth muscle. 
Unexpectedly, LacZ activity is undetectable in the endothelium of the kidney, spleen 
and testis. The non-vascular cells, including neuronal cells including Purkinje cells and 
neurons in the molecular layer, astrocytes, cardiomyocytes, cells in the marginal zone in 
spleen, and epithelial cells in the renal collecting duct express S1P1.  
In normal tissues of S1P2+/LacZ mice, LacZ activity is detected in various sizes of 
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blood vessels in a variety of organs, which include lung, brain, skeletal muscle, kidney, 
and liver [31]. Vascular cells are the major cell types that express S1P2 in many organs. 
Histological analysis using combined immunohistochemistry and X-gal staining showed 
that the endothelium in microvessels and both the endothelium and smooth muscle of 
larger vessels express S1P2. In addition, a limited population of bone marrow cells and a 
small number of non-vascular cells in the brain express S1P2.  
In contrast to S1P1, S1P2 and S1P3, the expression of the other two S1P receptors 
S1P4 and S1P5 is restricted: S1P4 and S1P5 are primarily expressed in lymphoid tissues 
and the lung, and the brain (especially oligodendrocytes), leukocytes and spleen, 
respectively [8, 11].      
 
Distinct signaling mechanisms of S1P1, S1P2 and S1P3   
The signaling mechanisms of S1P1~ S1P3 are better characterized compared with 
S1P4 and S1P5. S1P1, S1P2 and S1P3 activate overlapping yet distinctive intracellular 
signaling pathways, as analyzed by expressing cloned receptors in Chinese hamster 
ovary (CHO) cells and other cells (Fig. 2) [6-8, 11, 32, 33]. S1P1 couples exclusively to 
heterotrimeric Gi to activate Ras/ERK, PI 3-kinase/Akt, and Rho family small GTPase 
Rac. S1P1 also moderately activates phospholipase C (PLC) and consequently induces 
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Ca2+ mobilization [6, 7]. In contrast to S1P1, S1P2 and S1P3 couple to multiple G 
proteins, i.e. Gq, Gi and G12/13 [11, 32, 33]. S1P2 stimulates small GTPase Rho via G12/13, 
PLC mainly via Gq, ERK via Gi, and JNK and p38 mitogen-activated protein kinase 
(MAPK) via pertussis toxin (PTX)-insensitive G protein [32]. S1P2 mediates ERK 
activation obviously less potently compared with S1P1 and S1P3 [7, 33], suggesting 
inefficient Gi-coupling of S1P2. Regardless of the Gi-coupling of S1P2, S1P2 increases 
cyclic AMP. This was found to be mediated via G13 [34]. Like S1P2, S1P3 also couples 
to Gq-mediated PLC stimulation, G12/13-mediated Rho stimulation, and Gi-mediated 
ERK and Rac stimulation [11, 33]. S1P3 decreases or increases cyclic AMP level, 
depending on experimental conditions. Although S1P2 and S1P3 similarly can couple to 
Gq, Gi and G12/13 when overexpressed, obvious difference in the two receptor subtypes 
exists in primary cells: mouse embryonic fibroblasts (MEFs) from S1P2-null mice 
exhibit impaired Rho activation while PLC activation is not compromised compared 
with wild-type MEFs [11]. On the other hand, MEFs from S1P3-null mice show 
impaired PLC activation with Rho activation and adenylate cyclase inhibition 
unaffected. Although S1P3 deletion does not impair Rho activation in MEFs, S1P2- and 
S1P3-double null MEFs completely lack Rho activation response, suggesting that there 
is partial functional redundancy between S1P2 and S1P3.  S1P4 was reported to couple 
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to Gi and G12/13, which mediates ERK activation, PLC stimulation and Rho activation 
[11]. S1P5 couples to Gi and G12/13, resulting in adenylate cyclase inhibition and Ca2+ 
mobilization. 
Since S1P1, S1P2 and S1P3 are widely expressed, an integrated outcome of S1P 
signaling in a given cell type largely depends upon relative expression levels of the S1P 
receptor subtypes. In addition, ever growing numbers of examples of cross-talks 
between S1P receptor signaling and growth factor or cytokine receptor signaling have 
been reported. For example, under certain conditions S1P3 activation leads to activation 
of TGF signaling pathway and fibrosis. Update information regarding detailed 
cross-talk mechanisms is available in recently published excellent reviews [8, 35]. 
 
Regulation of cell migration by S1P receptor signaling 
Cell migration is a fundamental biological process essential for morphogenesis, 
angiogenesis, immune surveillance, inflammation, tumor cell invasion and metastasis 
[36]. It is regulated through receptor-mediated processes in response to a variety of 
ligands, which are either soluble, bound to extracellular matrix or expressed on cell 
surface.  
One of outstanding biological activities of S1P is the ability to regulate cell 
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migration either negatively or positively, which was first recognized to be apparently 
cell type-dependent [37]. S1P potently inhibits cell migration in a variety of tumor cells 
including B16 melanoma, breast cancer, and glioblastoma cells, as well as vascular 
smooth muscle cells. By contrast, S1P induces chemotaxis in vascular endothelial cells 
(ECs) [28], MEFs [11], and T and B lymphocytes [10, 12].  
CHO cells are an excellent model for studying mechanism of cell migration [38]. 
They vigorously exhibit stimulation or inhibition of cell migration, depending on 
stimuli. In a Boyden chamber assay in which cells are placed in the upper well, either 
S1P1 or S1P3 mediate migration of CHO cells toward S1P in the lower well, i.e. 
chemotaxis, with typical bell-shaped dose-response curves [38]. In contrast, S1P2 
mediates inhibition of cell migration directed toward a chemoattractant. This S1P2 effect 
is dependent on a concentration gradient of S1P: S1P2 mediates inhibition of cell 
migration toward a chemoattractant in the lower well, when S1P is placed only in the 
lower well. If S1P is placed only in the upper well or in both the upper and lower wells, 
chemotaxis is not suppressed. Therefore, S1P2 mediates chemorepulsion. Prostaglandin 
E2 (PGE2) and isoproterenol, which elevate the intracellular cyclic AMP level via Gs, 
also inhibit chemotaxis in CHO cells. However, the inhibitory effects of PGE2 and 
isoproterenol are distinct from the S1P2-mediated effect in that PGE2 and isoproterenol 
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effectively inhibit chemotaxis, whether these ligands are placed in the upper well or in 
both the upper and lower wells [39]. Thus, cell migration inhibition induced by PGE2 or 
isoproterenol is not dependent on their concentration gradients and therefore differs 
from chemorepulsion. Rho family GTPase Rac promotes actin polymerization to induce 
lamellipodia formation and plays a pivotal role in cell migration. The chemoattractant 
receptors S1P1 and S1P3 mediate Rac activation via Gi, whereas chemorepellant 
receptor S1P2 does not [38]. Importantly, S1P2 but not S1P1 or S1P3 inhibits Rac 
activation induced by a chemoattractant. S1P2-mediated inhibition of Rac activation and 
cell migration in response to a chemoattractant is abolished by the expression of 
dominant negative Rho mutant N19Rho and inhibition of S1P2-G12/13 coupling, 
indicating that Rho mediates Rac inhibition in S1P2-expressing cells. Detailed analysis 
suggests the involvement of stimulation of Rac GTPase-activating protein (GAP) in Rac 
inhibition in a manner independent of a Rho kinase [38]. Rac activation by a 
chemoattractant, whether it is a ligand for a GPCR or a receptor tyrosine kinase, is at 
least in part dependent on PI 3-kinase. The product of PI 3-kinase produces PI-3,4,5-P3, 
which mediates recruitment and activation of signaling molecules including a 
Rac-guanine nucleotide exchange factor such as Tiam-1. PI-3,4,5-P3 is 
de-phosphorylated by the 3’-specific phosphoinositide phosphatase “Phosphatase and 
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Tensin Homolog Deleted from Chromosome 10” (PTEN). PTEN was found to be 
stimulated by S1P2 [40]. However, S1P2-mediated inhibition of Rac and migration does 
not seem to involve inhibition of PI 3-kinase or stimulation of PTEN [41]. S1P2 
mediates elevation of cyclic AMP, which could mediate inhibition of cell migration. 
However, this is also unlikely because different from the cases of PGE2 and 
isoproterenol as stated above, S1P2 activation induces chemorepulsion. Various cells, e.g. 
endothelial cells and smooth muscle cells, express multiple S1P receptor subtypes. A net 
effect of S1P on cell migration is likely determined by integration of the counteracting 
signals input by the chemoattractant receptors S1P1 and S1P3 and the chemorepellent 
receptor S1P2.                            
 
Regulation of vascular formation by S1P receptor signaling 
Angiogenesis is a complex process comprising EC proliferation and migration, 
cell-cell adhesion, and mural cell recruitment [36]. The first discovery of an in vivo 
angiogenic activity of S1P came from the observation that S1P stimulated angiogenesis 
in the Matrigel implants in mice. S1P induced directed migration of endothelial cells via 
Gi and proliferation [28]. S1P also facilitates adherens junction assembly in an 
S1P1-Gi-Rac- and S1P3-G12/13-Rho-dependent manner, leading to stimulation of 
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capillary-like tube formation. S1P1-null mouse embryo is defective in recruiting 
pericytes and SMCs to vessels, i.e. vascular maturation or stabilization [9] (see below 
for more detail). Conditional EC-specific deletion of S1P1 results in the similar vascular 
maturation defect to global S1P1 deletion, indicating that vessel coverage by mural cells 
is directed by S1P1 in ECs. In contrast to S1P1-null mice, either S1P2- or S1P3-single 
null mice are alive without a vascular formation defect. However, compared with mice 
null for S1P1 alone, embryos null for both S1P1 and S1P2, null for both S1P1 and S1P3, 
and null for all of S1P1, S1P2 and S1P3 exhibit more severe vascular phenotypes 
including a vascular maturation defect and hemorrhage with earlier intrauterine death 
[42]. S1P1 is the most important receptor for vascular development while S1P2 and S1P3 
possess partially redundant and cooperative functions in S1P regulation of vascular 
formation.  
S1P signaling is involved in pathological angiogenesis including tumor 
neovascularization. In a tumor cell implantation model in mice, S1P1 is upregulated in 
vessels at sites of tumor implantation [15]. S1P1 silencing by repeated local injections of 
S1P1-specific siRNA suppresses tumor angiogenesis and vascular maturation. 
Administration of monoclonal anti-S1P neutralizing antibody inhibits tumor growth 
[43]. The effectiveness of anti-S1P antibody is substantial and more than that obtained 
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with monoclonal anti-VEGF antibody. This anti-tumor effect is likely due to inhibition 
of both angiogenesis and tumor cell motility, survival and proliferation [44]. 
Interestingly, anti-S1P antibody suppresses VEGF- and FGF-induced angiogenesis in 
Matrigel plugs in mice, suggesting that endogenous S1P plays a permissive role in 
angiogenesis or functions downstream of VEGF and FGF.  
In contrast to S1P1, S1P2, which is also expressed in ECs, inhibits growth 
factor-induced Rac activation, cell migration and capillary-like tube formation via a 
G12/13/Rho-dependent mechanism [38]. The S1P2-selective antagonist JTE-013 enhances 
S1P-induced angiogenesis in Matrigel plugs in mice [36]. In murine retinal 
angiogenesis model, S1P2 inhibits post-natal physiological angiogenesis in avascular 
areas of the retina [45]. Thus, different from S1P1, S1P2 is a negative regulator of 
angiogenesis. S1P2 deletion enhances angiogenesis in implanted tumors with 
accelerated tumor growth [31]. In tumors, S1P2 is expressed in ECs and mural cells in 
tumor vessels. In S1P2-null mice, the coverage of tumor neovessels with pericytes and 
SMCs is enhanced compared with wild-type mice. VEGF- and FGF2-induced 
microvascular formation and mural cell coverage in matrigel plugs are also enhanced in 
S1P2-null mice, suggesting that angiogenesis induced by these growth factors is 
egatively affected by S1P2.  
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The ECs isolated from S1P2-null mice display altered phenotypes compared with 
wild-type ECs: S1P2-null ECs show increased cell proliferation, migration and the 
formation of tube-like tube structures in response to growth factors compared with 
wild-type ECs [31]. In S1P2-null MLECs, two major changes in the intracellular signals 
are noted. Both the basal and S1P-stimulated activities of Rac are greater in S1P2-null 
ECs compared with wild-type ECs. Secondly, in wild-type ECs S1P inhibits 
VEGF-induced activation of Akt but not ERK whereas S1P fails to inhibit Akt 
activation in S1P2-null ECs. Thus, S1P2 seems to mediate S1P-induced Akt inhibition in 
wild-type ECs. The Akt inhibition is probably mediated through PTEN stimulation, 
which reduces amount of PI-3,4,5-P3 [40]. Thus, S1P2 inhibition of angiogenesis 
involves the G12/13-Rho-Rac/PTEN signaling pathway in ECs.  
In addition to ECs, S1P2 is also expressed in CD11b+ positive bone marrow-derived 
cells (BMDCs) in the tumor stroma [31]. Myeloid cells including CD11b+ cells 
participate in tumor angiogenesis through multiple mechanisms [36]. Infiltrating 
myeloid cells in tumors release pro-angiogenic factors including VEGFs, FGF-2, 
PDGFs and matrix metalloproteases (MMPs), the enzymes that contribute to 
angiogenesis through degradation of the extracellular matrix proteins and resultant 
release of VEGFs and TGF that has been deposited in the matrix. A subpopulation of 
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BMDCs is capable of transdifferentiating into vascular ECs and become incorporated 
into the new blood vessels in tumors. In S1P2-null mice, CD11b+ cells infiltrating into 
tumors are increased compared with wild-type mice [31]. Bone marrow chimera 
experiments document that S1P2 in BMDCs exerts an inhibitory effect on tumor 
angiogenesis. 
Thus, S1P2 exerts inhibitory effects on tumor angiogenesis through both the 
EC-autonomous and myeloid cell-dependent actions. These S1P2 actions open the 
possibility of a novel anti-angiogenic therapy to target S1P2. It is an interesting 
possibility that S1P receptor subtype-selective pharmacological targeting strategies, i.e. 
S1P1 inhibition in combination with S1P2 activation, could lead to more effective 
inhibition of tumor angiogenesis. In addition to an expected anti-angiogenic action of 
S1P2-selective agonist, S1P2 stimulation in tumor cells could directly inhibit tumor 
progression in vivo, leading to inhibition of invasion and metastasis, as previously 
demonstrated [44, 46]. 
 
Regulation of vascular homeostasis by S1P receptor signaling 
   S1P regulates vascular tone by acting on both the endothelium and smooth muscle 
through multiple S1P receptors. In ECs, S1P1 is most abundant with S1P2 and S1P3 
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being expressed at much lower levels, whereas in smooth muscle the expression of S1P2 
and S1P3 are abundant with S1P1 expression being very low [13]. S1P-induced 
relaxation is mediated through its action on the endothelium whereas S1P directly 
contracts smooth muscle. In ECs, S1P stimulates a calmodulin-dependent enzyme, 
eNOS, which produces nitric oxide (NO). NO diffuses into the underlying smooth 
muscle to induce relaxation through generating cyclic GMP. This S1P action is mediated 
via S1P1 and S1P3, which activate Akt through PI 3-kinase to phosphorylate eNOS [47]. 
S1P1 and S1P3 also activate PLC to mobilize Ca2+, which fully activates eNOS in 
concert with Akt-mediated phosphorylation. Although Gq-coupled S1P3 more robustly 
activates PLC compared with Gi-coupled S1P1, the contribution of S1P1 seems to 
dominate in eNOS stimulation because S1P1 expression is higher in ECs compared with 
S1P3. In smooth muscle, S1P activates Rho and Rho kinase via S1P2/S1P3 and G12/13 
[41]. Rho kinase phosphorylates the myosin targeting subunit, MYPT1, of myosin 
phosphatase and the myosin phosphatase inhibitor protein, CPI-17, to inhibit myosin 
phosphatase. The myosin light chain kinase activation by PLC-Ca2+, together with 
myosin phosphatase inhibition by Rho-Rho kinase, efficiently increases myosin light 
chain phosphorylation and, thereby, vascular contraction. S1P2 is also suggested to 
contribute to vascular tone through a mechanism involving the action on the 
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endothelium although the precise mechanism remains to be defined [48].  
S1P contributes to vascular barrier integrity. Initially, S1P was found to enhance 
barrier function of an EC monolayer and to protect barrier disruption induced by the 
edemagenic agent thrombin [49]. This effect is mediated by S1P1 and, to the lesser 
extent, S1P3 through Gi-PI 3-kinase-Rac. In contrast to S1P1, S1P2, when overexpressed 
in vitro in ECs, disrupts barrier integrity via Rho-Rho kinase-PTEN pathway [50].  
Endothelial barrier dysfunction, which increases vascular permeability, occurs in 
inflammation, tumor neovessels and atherosclerotic lesions. Challenge with 
lipopolysaccharide (LPS) or thrombin induces an increase in pulmonary microvascular 
permeability. S1P1+/- mice exhibited reductions in barrier protection by administering a 
moderate dose of S1P or the S1P1-selective agonist SEW-2871, after LPS challenge 
[51]. In contrast, S1P2-/- mice were protected from LPS-induced barrier disruption 
compared with wild-type mice. Barier disruption is also enhanced in SphK1-null mice. 
Adenoviral transduction of SphK1 into the lung protects mice from barrier disruption 
whereas that of SphK2 rather augments it, indicating the distinct roles of SphK1 and 
SphK2 [52]. The intravenous or intratracheal administration of S1P is protective against 
LPS-induced barrier disruption [51]. However, a higher dose of S1P or repeated 
administration of S1P1 agonists (FTY720 and AUY954) rather exacerbates barrier 
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disruption by stimulating internalization and degradation of S1P1 protein in a lung 
injury model [53], highlighting the importance of S1P1 agonist concentration.  
Plasma S1P concentration is another critical determinant for maintaining barrier 
integrity. In inducibly SphK1-deleted mice with SphK1fl/-:SphK2-/-/Mx1-Cre Tg+ 
(S1Pless mice), which show approximately 30 nM plasma S1P compared with 2.5 M 
in control mice, vascular leak on anaphylaxis and administration of platelet-activating 
factor or histamine is augmented with impaired survival [16]. Transfusion of 
erythrocytes, which restores plasma S1P levels, or acute administration of an S1P1 
agonist reverse vascular leak and prevent death. In contrast, SphK2-null mice have a 
rapid recovery from anaphylaxis [54]. S1P2- but not S1P3- null mice also show poor 
recovery from anaphylaxis. S1P infusion fails to promote recovery of S1P2-null mice 
from anaphylaxis.  
Physiological levels of endothelial S1P1 and SphK1-produced S1P serve a 
constitutive maintaining role for vascular barrier function. Exogenous 
supraphysiological S1P1 agonists impair this mechanism by downregulating S1P1. 
Furthermore, S1P2 participates in the vascular protection from anaphylaxis although the 




Modulation of leukocyte functions and inflammation by S1P signaling 
The role of S1P signaling as significant modulator of leukocyte functions and 
inflammation has emerged. SphK1-derived S1P regulates pro-inflammatory signaling 
pathways, including activation of nuclear factor-κB [55]. S1P1 regulates endothelial 
barrier integrity as stated above [49-52, 56]; cytokine and adhesion molecule expression, 
lymphocyte maturation, differentiation and trafficking, and mast cell migration. S1P2 
also regulates B lymphocyte survival and confinement in lymph node follicles [57]. 
S1P3 modulate dendritic cell trafficking and activation. In addition, S1P5 regulates NK 
cell trafficking [12].  
   S1P1-Gi signaling pathway regulates trafficking of lymphocytes and other immune 
cells by directing migration of immune cells toward a compartment with a relatively 
higher S1P concentration. Therefore, the existence of a S1P concentration gradient 
between compartments, e.g. lymphoid tissue parenchyma and blood plasma/lymphatic 
fluid, which is created and maintained by the SphK-catalyzed S1P production by 
erythrocytes and vascular/lymphatic endothelial cells and SPL- and LPP3-catalyzed S1P 
degradation in lymphoid tissue parenchyma, is critical. S1P1 expression on the cell 
surface of lymphocytes and other immune cells is maintained in a low S1P environment 
in the thymus and lymph nodes, through its inhibited internalization/degradation or 
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upregulation as a result of lymphocyte maturation and interaction with other immune 
cells within lymphoid tissues [12]. S1P1 also participates in the regulation of 
lymphocyte recirculation through tightening the cell-cell junction of sinus-lining ECs 
[56]. S1P2-G12/13 pathway ensures the localization of S1P2-expressing B cells in a 
follicular center in lymph nodes [57]: S1P concentration is higher at the follicle 
perimeter than the follicular center due to S1P production by stromal cells abundant at 
the perimeter and rapid S1P degradation by follicular B cells in the center. In the 
presence of this S1P concentration gradient, migration of S1P2-expressing B cells from 
the center to the perimeter of a follicle is impeded by the chemorepellent activity of 
S1P2 through Rho-induced Rac inhibition. The low S1P environment at the follicular 
center also favors survival and proliferation of S1P2-expressing B cells because the 
mitogenic and survival signaling molecule Akt, which is negatively regulated by 
S1P2-G12/13-Rho-PTEN, is spared from suppression. 
   SphK1 are involved in inflammation through both the extracellular messenger and 
intracellular messenger actions of S1P [12]. In a septic model due to bacterial peritonitis, 
thrombin, which is produced by coagulation reaction, binds to and activates the GPCR 
proptease-activated receptor-1 (PAR1) on dendritic cells involved in innate immunity 
[58]. The activation of PAR1 in turn stimulates SphK1, S1P export to the cell exterior, 
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and S1P3 activation, which induces amplification of inflammation by stimulating the 
production of IL-1 and tissue factor from dendritic cells and disrupting EC barrier 
function. SphK1 is also implicated in the actions of tumor necrosis factor (TNF) and 
other cytokines, in which intracellular S1P produced by SphK1 binds to TRAF2 and 
thereby activates NE-B [55]. Disruption of SphK1 gene alleviates inflammatory 
diseases including colitis and arthritis, providing further support for the involvement of 
SphK1 in inflammatory responses [12]. In addition to the intracellular action of 
SphK1-generated S1P, a recent study [59] showed that S1P produced by SphK2 in the 
nucleus bound to the histone deacetylases HDAC1 and HDAC2 and inhibited their 
enzymatic activity, which suggested that HDACs are direct intracellular targets of S1P. 
Furthermore, S1P generated by SphK2 in mitochondria plays the important role in 




There is now broad consensus that S1P signaling plays a crucial role in the 
physiology and pathophysiology of the cardiovascular, immune and other systems. 
Observations obtained with gene-engineered mice and pharmacological tools to target 
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receptors and enzymes rapidly promote our understsanding S1P functions. Investigation 
in more depth into involvements of S1P signaling in various diseases, in combination 
with development of drugs with improved specificity and efficacy and their optimal 
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Figure 1. Sphingolipid metabolism in various subcellular compartments  
Ceramide (Cer) is produced either by de novo synthesis from palmitoyl CoA 
(palmCoA) and serine with sequential enzymatic reactions in endoplasmic reticulum 
(ER) or through degradation of sphingomyelin (SM) by the action of sphingomyelinases 
in the plasma membrane and intracellular membranes including lysosomes. Cer is 
deacylated by ceramidase to yield sphingosine (Sph), which is then phosphorylated by 
SphK1/2 to generate S1P. S1P is exported through a plasma membrane S1P transporter, 
leading to activation of the G protein-coupled S1P receptor subtypes (S1P1~S1P5). S1P 
could be either dephosphorylated by S1P phosphatase1/2 (SPP) and lipid phosphate 
phosphatase1-3 (LPP) back to Sph or degraded to ethanolamine-phosphate (Eth-P) and 
hexadecenal (hxdcnl) by S1P lyase (SPL) to leave sphingolipid metabolic pathway. 
SphK1 is present in both cytosolic and membrane-bound fractions, both being 
enzymatically active. SPPs and SPL are located in ER. At least, a subtype of LPPs 
exists on the plasma membrane. Intracellular transfer of Cer from ER to Golgi is 
facilitated by transfer proteins such as CERT, and both Cer and SM traffic between 




Figure 2.  S1P receptor subtype-specific heterotrimeric G protein coupling and 
intracellular signaling mechanisms  
S1P1 couples exclusively to Gi to activate Ras-ERK and PI 3-kinase-Akt/Rac pathways, 
leading to stimulation of chemotaxis and cell proliferation. S1P2 couples to multiple G 
proteins, especially to G12/13 to induce robust Rho activation, leading to inhibition of 
Rac and cell migration, and also inhibition of cell proliferation via inhibition of Akt.  
S1P2 also couples to stimulation of adenylate cyclase via G13. S1P3 activates 
Gq-PLC-Ca2+ pathway, and Gi-Ras-ERK and Gi-PI 3-kinase-Akt/Rac pathways. 
S1P3-G12/13-Rho pathway becomes evident only when Gi is inhibited by pertussis toxin. 
 
 



